ABSI: December brings the interim hair-loss readout; 26-week data are planned for 2027
Absci Corporation (ABSI) anticipates an interim readout in December for its prolactin receptor-targeting hair-loss program, with comprehensive 26-week data expected in 2027. The company estimates the potential U.S. market for this treatment to exceed $25 billion and plans to initiate an endometriosis study in mid-2027. This information is based on an AI-generated summary of the Jefferies Global Healthcare Conference Audio Transcript from November 18, 2026.
Weekly Recap: Q3 financial results and clinical trial timelines
Absci Corporation (NASDAQ:ABSI) reported a 20% year-over-year revenue decline in Q3 2026, reaching $304,000, alongside a $33.3 million net loss. Despite this, the company's cash reserves of $173.7 million are expected to fund operations into the second half of 2028. Absci also provided updates on its clinical trial timelines, anticipating interim data from its Phase 1/2a hair-loss trial in December 2026 and planning a Phase 2 endometriosis trial for mid-2027.
Absci (NASDAQ:ABSI) Stock Falls 9.6% Following Analyst Downgrade
Absci (NASDAQ:ABSI) shares dropped 9.6% after Guggenheim lowered its price target from $15 to $14, while maintaining a Buy rating. Despite the downgrade, analyst sentiment remains largely positive, with a consensus "Moderate Buy" rating and an average target of $14.90. The company recently reported a quarterly loss of $0.19 per share, matching estimates, but revenue of $0.30 million fell short of analysts' forecasts.
Guggenheim Has Lowered Expectations for Absci (NASDAQ:ABSI) Stock Price
Guggenheim lowered its price target for Absci (NASDAQ:ABSI) from $15 to $14 but reiterated a "Buy" rating, implying a potential upside of 81% from its current price. This follows Absci reporting quarterly EPS in line with estimates at a loss of $0.19 per share, but revenue of $0.30 million fell below the consensus estimate of $0.66 million, causing shares to open down 8.5% at $7.73. Despite the lowered target, analyst sentiment remains largely positive, with a consensus "Moderate Buy" rating and an average price target of $14.90.
Absci stock price target lowered to $14 by Guggenheim on model adjustments
Guggenheim has reduced its price target for Absci Corp. (NASDAQ:ABSI) shares to $14 from $15, while maintaining a Buy rating. This adjustment follows Absci's third-quarter 2026 results and model updates, including a switch to a fully diluted share count in their discounted cash flow analysis. The stock is expected to remain volatile, particularly around the December release of interim data from its HEADLINE trial for ABS-201.
Absci stock price target lowered to $14 by Guggenheim on model adjustments
Guggenheim has lowered its price target for Absci Corp. (NASDAQ:ABSI) shares to $14 from $15, while maintaining a Buy rating. This adjustment follows the company's third-quarter 2026 results and model updates, including a switch to a fully diluted share count in their discounted cash flow analysis. Investors are cautioned about potential stock volatility around the upcoming December data release for Absci's HEADLINE trial.
Absci Corporation (ABSI) Seasonal Returns Chart - Yahoo Finance
The article provides a seasonal returns chart for Absci Corporation (ABSI) on Yahoo Finance, showing the average monthly price return from 2021 to 2026. It also includes real-time and after-hours stock prices for ABSI, along with various financial metrics and market data.
Catherine D. Wood and ARK report an Absci (ABSI) stake above 5% as of September 30.
ARK Investment Management LLC and Catherine D. Wood have reported an amended beneficial-ownership stake in Absci Corp (ABSI), holding 11,928,917 shares, or 6.95% of the common stock, as of September 30, 2026. ARK exercises sole voting and dispositive power over these shares, while Catherine D. Wood reports shared voting and dispositive power. The report specifies that the ARK Genomic Revolution ETF is the only client with an interest exceeding 5% in these securities.
Form SCHEDULE 13G/A Absci Corp Filed by: ARK Investment Management LLC
ARK Investment Management LLC and Catherine D. Wood have filed an Amendment No. 3 to Schedule 13G for Absci Corp (ABSI). The filing indicates that ARK Investment Management LLC and Catherine D. Wood beneficially own 11,928,917 shares of Absci Corp common stock, representing 6.95% of the class. This amendment updates their ownership position in the company as of September 30, 2026.
Absci Releases Q3 2026 Financial Results
Absci Corporation reported a narrower-than-expected loss in Q3 2026, with a basic and diluted loss of $0.19 per share, beating analyst estimates by 5.0%. However, the company's revenue of $304,000 fell short of Wall Street forecasts, representing a 19.6% decrease from the prior year. Despite the revenue miss, analysts maintain a positive outlook on the clinical-stage biopharmaceutical company's prospects, with a consensus of 11 buy ratings.
Revenue falls 20% at Absci (ABSI) as quarterly losses widen.
Absci (ABSI) reported a 20% decline in Q3 2026 partner program revenue to $304,000, with year-to-date revenue falling 61% to $837,000, attributing the drop to project-milestone timing. The company's net loss widened to $33.3 million for the quarter and $96.1 million for the nine months. Despite widening losses, Absci anticipates its $173.7 million in cash, cash equivalents, and marketable securities will cover operating expenses for at least the next 12 months, as its lead candidate ABS-201 progresses in Phase 1/2a trials for pattern hair loss.
Absci Q3 Earnings Call Highlights
Absci (ABSI) announced updates from its Q3 earnings call, highlighting expected interim data in December for its experimental pattern hair loss treatment (ABS-201) and a Phase II trial planned for mid-2027 for endometriosis. The company ended September with $173.7 million in cash, expected to fund operations into the second half of 2028, and is advancing its clinical pipeline while increasing R&D expenses.
Absci Matches The Whisper, But Endometriosis Delay And Rising Burn Make December's Hair-Loss Readout The Whole Story
Absci reported a third-quarter loss that matched expectations, but revenue missed significantly. The company's hair-loss drug readout is now a key near-term catalyst in December, while the endometriosis program has been delayed. Rising R&D costs and a cautious tone around the hair-loss data suggest the December readout is critical for the stock's investment case.
Absci Q3 2026 Earnings Call Transcript
Absci reported increased R&D expenses to $23.6 million for Q3 2026, driven by ABS201 development, and SG&A expenses rose due to stock-based compensation. The company plans to release interim 13-week proof-of-concept data for ABS201 in pattern hair loss next month, with full 26-week data expected early next year, and aims to start a Phase 2 trial for ABS201 in endometriosis by mid-2027. Absci's cash reserves of $173.7 million are projected to fund operations into the second half of 2028, as the company focuses on expanding its prolactin receptor antibody franchise and developing direct-to-consumer programs.
Absci Corporation (ABSI) files mixed shelf
Absci Corporation (ABSI) has filed a mixed shelf offering, which includes common stock, preferred stock, debt securities, warrants, and units. This filing provides the company with flexibility to raise capital in the future. As of November 12, 2026, Absci's stock price was $9.72, down 3.95%, and its overall analyst rating was a "SELL" with a revenue growth of +83.6%.
ABSI: SEC Form S-3ASR filed by Absci Corporation
Absci Corporation (ABSI) filed a Form S-3ASR, an automatic shelf registration statement, which allows the company to offer various securities in the future. This filing does not specify an amount or a particular offering, meaning the timing and size of any potential sale are currently unknown. While it provides Absci with a mechanism to raise capital, such future sales could lead to dilution for existing shareholders if new stock is issued.
Absci Q3 2026: December hair-loss data is the only number that matters
Absci's Q3 2026 financial results showed an EPS beat but a revenue miss, though these figures are largely overshadowed by the upcoming December release of 13-week interim hair-loss data from its HEADLINE trial of ABS-201. The company, an AI drug designer with a $1.7 billion market cap, has sufficient cash to fund operations into late 2028, making the ABS-201 trial results critical for its future trajectory and potential progression to Phase 3. Absci also appointed a Chief Commercial Officer, indicating early preparations for commercialization.
Absci Corporation Tokenized Stock (Coinbase) price today, ABSIc to USD live price, marketcap and chart
This CoinMarketCap page provides information on Absci Corporation Tokenized Stock (Coinbase) (ABSIc), including its live price, market cap, and charts. It notes that this is a preview page and offers details on how to access ABSIc data through the CoinMarketCap API for developers. The page also features popular real-world assets, most visited cryptocurrencies, and trending conversions.
ABSI: Absci Corporation filed SEC Form 8-K: Results of Operations...
Absci Corporation (ABSI) filed an SEC Form 8-K, reporting its Q3 2026 financial results with revenue of $0.3 million and a net loss of $33.3 million, an increase from the prior year. The company anticipates interim proof-of-concept data for its ABS-201 hair loss program next month and has appointed Gerry Muhle as Chief Commercial Officer. Shareholders are keenly awaiting the ABS-201 trial results amidst rising losses.
Cathie Wood’s ARK sells Absci stock, buys Prime Medicine
Cathie Wood's ARK ETFs made several strategic trades on November 11, 2026, significantly increasing its stake in Prime Medicine and Archer Aviation. Concurrently, ARK reduced its holdings in Absci Corp, BYD Company Limited, Honeywell Aerospace, and Teradyne, indicating a shift towards biotechnology and aerospace sectors while divesting from others.
Earnings To Watch: Absci Corp (ABSI) Q3 2026 -- GF Value Sees 16% Downside
Absci Corp (NASDAQ:ABSI) is scheduled to release its Q3 2026 earnings on November 12, 2026, with revenue expected at $0.73 million and an earnings per share of -$0.20. While analysts project a 48.63% upside to an average price target of $14.82, GuruFocus estimates a 16.15% downside with a GF Value of $8.36. The average brokerage recommendation for Absci is "Outperform."
ABSI: ABS-201 readouts are approaching, with cash runway into H2 2028
Absci Corporation (ABSI) is making progress with its ABS-201 drug candidate, which is being developed for pattern hair loss and endometriosis. Interim analysis for male hair growth is anticipated next month, with proof-of-concept data expected early next year, and a Phase II trial for endometriosis is scheduled for mid-next year. The company's cash runway is projected to last into the second half of 2028.
Absci (ABSI) On AI Drug Pipeline Debate While Rich Valuation Stays In Focus
Absci (ABSI) is facing scrutiny over its high price-to-book ratio, given its status as a loss-making biotech with an AI-driven drug pipeline and ongoing cash needs. Despite recent stock volatility, Absci has seen significant share price and shareholder returns over the past year. Analysts see a fair value of $14.90 per share, believing its lead antibody ABS-201 and AI technology partnerships could improve its financial profile, though execution risks and competition remain concerns.
Weekly Recap: Jefferies Buy rating and Absci joins three conferences
Jefferies initiated coverage of Absci Corporation (NASDAQ:ABSI) with a Buy rating and a $14 price target. Absci is scheduled to participate in three healthcare investor conferences: Guggenheim on November 10, Jefferies on November 18, and Evercore on December 1, 2026.
Absci Corp (ABSI) Stock Forecast & Analyst Ratings
This article provides an analysis of Absci Corp (ABSI) stock, including its current price, market capitalization, and analyst ratings. It highlights that analysts have assigned a consensus rating of "Hold" to ABSI, with specific price targets and a review of recent performance.
Absci Corporation (ABSI) Seasonal returns chart
The article presents a seasonal returns chart for Absci Corporation (ABSI), showing the average monthly price return from 2021 to 2026. As of October 30th, Absci's stock price was $11.13, with a pre-market increase to $11.50. This chart helps investors visualize potential seasonal trends in the stock's performance.
Absci Corp stock hits 52-week high at 12.06 USD
Absci Corp's stock reached a 52-week high of $12.05, demonstrating a 27% increase over the past week and an impressive 240% year-to-date return. This surge, reflecting strong investor confidence, occurs despite a wider-than-expected Q2 loss and delayed Phase 2 trial for an endometriosis treatment. The company's hair loss drug, ABS-201, shows promise, with analysts from Jefferies and Guggenheim maintaining Buy ratings.
Jefferies Initiates Absci Corp(ABSI.US) With Buy Rating, Announces Target Price $14
Jefferies has initiated coverage on Absci Corp (ABSI.US) with a Buy rating. The investment bank also announced a target price of $14 for the company's stock.
Absci Corp stock hits 52-week high at 12.06 USD By Investing.com
Absci Corp (ABSI) stock recently hit a 52-week high of $12.05, trading at $11.95 with significant gains over the past week and year-to-date. This surge reflects strong investor confidence despite a wider-than-expected Q2 loss and delayed Phase 2 trial for an endometriosis treatment. Analysts, including Jefferies and Guggenheim, maintain Buy ratings, citing potential in its hair loss drug and the company's substantial cash reserves.
Jefferies initiates Absci stock with buy on hair loss drug potential
Jefferies initiated coverage on Absci Corp. (NASDAQ:ABSI) with a Buy rating and a $14.00 price target, citing the potential of its hair loss drug candidate, ABS-201, which is expected to achieve $2 billion to $3 billion in peak sales. Despite the stock trading near its 52-week high after a 240% year-to-date surge, InvestingPro analysis suggests it is overvalued. The company recently reported a second-quarter loss that missed analyst expectations and postponed the start of its endometriosis treatment trial.
Absci Soars 12%, Schrödinger Up 11%, Recursion Up 9% as AI Drug Discovery Stocks Rally
Shares of Absci, Schrödinger, and Recursion, all prominent in AI drug discovery, rallied significantly today, with Absci up 12%, Schrödinger up 11%, and Recursion up 9%. The surge appears to be a "risk-on" market day rather than company-specific news, though Schrödinger's gains have more fundamental business backing. Absci, in particular, with minimal revenue, seems to be driven largely by investor sentiment and a bet on its ABS-201 trial.
BlackRock reports 13.4M Absci (ABSI) shares in an amended passive stake disclosure.
BlackRock, Inc. has filed an amended passive investment disclosure (Schedule 13G/A) for Absci Corp (ABSI), reporting beneficial ownership of 13,396,310 common shares, which represents 7.8% of the class. The filing specifies that BlackRock holds sole voting power over 13,106,779 shares and sole dispositive power over 13,396,310 shares, with no shared powers. This ownership reflects holdings by certain BlackRock business units and affiliates, with various persons potentially receiving dividends or sale proceeds, though no single person's interest exceeds 5%.
How Investors Are Reacting To Absci (ABSI) Early Hair Loss Trial Data
Absci (ABSI) reported positive interim Phase 1 results for ABS-201 in pattern hair loss, indicating an antibody half-life of at least 65 days. This data supports ongoing clinical work and shifts Absci's investment focus onto this single biologic program, with an increased reliance on its success before the cash runway tightens in early 2028. The company's future hinges on clinical data for ABS-201 and its ability to attract partnerships to supplement revenue and support its pipeline.
Absci Corporation Estimates – NASDAQ:ABSI
This article provides an overview of Absci Corporation (NASDAQ: ABSI) financial data and analyst estimates available on TradingView. It highlights sections for income statement, balance sheet, cash flow, and valuation metrics, allowing users to compare actual results with average, high, and low estimates. The content emphasizes that the information is not investment advice and encourages users to conduct their own research.
Absci (NASDAQ:ABSI) Shares Climb 5.8% Following Analyst Upgrade
Absci (NASDAQ:ABSI) shares rose 5.8% after KeyCorp increased its price target from $16.00 to $20.00 while maintaining an "overweight" rating. The company has a consensus "Moderate Buy" rating from analysts with an average price target of $14.56. Despite positive analyst sentiment, Absci missed Q2 earnings estimates, reporting a loss of $0.21 per share and revenue of $0.32 million.
KeyBanc Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $20
KeyBanc has reiterated its Buy rating for Absci Corp (ABSI.US) and increased its price target to $20. This indicates a positive outlook from the investment bank on the company's future performance and stock value.
ABSI Maintained by Keybanc -- Price Target Raised to $20.00
Keybanc analyst Scott Schoenhaus maintained an "Overweight" rating for Absci (ABSI) and raised its price target from $16.00 to $20.00, indicating confidence in the company's biotechnology potential. Despite this bullish analyst outlook and strong momentum, GuruFocus indicates ABSI is significantly overvalued by 500% at its current price of $8.88, with a low profitability score. Investors are advised to consider the discrepancy between market price and intrinsic value.
Absci Corp | 4: Statement of changes in beneficial ownership of securities-Officer Jonasson Zachariah
This document is a Form 4 filing for Absci Corp, detailing changes in beneficial ownership of securities for officer Jonasson Zachariah. It indicates required disclosure of stock transactions by an insider.
Form 4 Absci Corp: Todd Bedrick (SVP, CAO) For: 12 October
The article reports on a Form 4 filing for Absci Corp, detailing a transaction involving Todd Bedrick, SVP and CAO of the company, on October 12th. It provides this specific insider trading information without further details or analysis. The article is from Investing.com and was published on October 15, 2026.
Form 4 Absci Corp: Sean McClain (Director, CEO) For: 12 October
This article reports a Form 4 filing for Absci Corp, indicating that Sean McClain, who serves as both a Director and CEO, had a transaction on October 12th. The article provides the title and the company and individual involved, but no further details about the nature of the transaction.
Form 4 Absci Corp: Sean McClain (Director, CEO) For: 12 October
This article reports on a Form 4 filing for Absci Corp, indicating that Sean McClain, a Director and CEO, made a transaction on October 12. The brief news item includes the company's stock symbol ABSI and its current performance of -3.96%.
Form 4 Absci Corp For: Oct 12 Filed by: Bedrick Todd
This article reports a Form 4 filing by Todd Bedrick, SVP and CAO of Absci Corp (ABSI), detailing a transaction on October 12, 2026. The filing indicates a disposition of 22,325 shares of common stock at $10.16 per share, representing shares withheld by the issuer for tax obligations related to restricted stock unit vesting. Following this transaction, Bedrick beneficially owns 199,128 shares directly.
H.C. Wainwright Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $16
H.C. Wainwright has reiterated its Buy rating for Absci Corp (ABSI.US) and maintained its target price at $16. This indicates the firm's continued confidence in the company's stock performance.
Press Release: Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026
Absci (NASDAQ: ABSI) announced that it will report its business updates and financial and operating results for the third quarter of 2026 on Thursday, November 12, 2026. The company will also host a conference call and webcast on the same day to discuss these results. Interested parties can access the webcast and accompanying slides on Absci's investor relations website.
Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026
Absci Corporation announced it will report business updates and financial results for the third quarter of 2026 on Thursday, November 12, 2026, before market open. Management will host a conference call and webcast to discuss developments, results, and outlook. Absci is a clinical-stage biopharmaceutical company using generative AI for drug discovery, including its ABS-201™ therapeutic for hair regrowth and endometriosis.
Absci Price Target Raised to $15.00/Share From $14.00 by JP Morgan
JP Morgan has increased its price target for Absci to $15.00 per share, up from the previous target of $14.00. This adjustment reflects an updated outlook on the company's financial prospects and potential growth.
Absci (NASDAQ:ABSI) Stock Price Target Raised at JPMorgan Chase & Co.
JPMorgan Chase & Co. raised its price target for Absci (NASDAQ:ABSI) to $15.00 from $14.00, reiterating an "overweight" rating and suggesting a 55.68% upside. This comes despite Absci missing Q2 earnings estimates with a $0.21 per-share loss and $0.32 million in revenue, compared to analyst expectations. The stock currently holds a "Moderate Buy" consensus rating from analysts, with an average price target of $13.88.
Absci (NASDAQ:ABSI) Stock Rating Reaffirmed as Buy by HC Wainwright
HC Wainwright has reiterated its "Buy" rating for Absci (NASDAQ:ABSI), setting a $16 price target that suggests a 65.46% upside. Despite the positive analyst sentiment and an average "Moderate Buy" rating from multiple firms, Absci recently missed its quarterly earnings and revenue estimates and continues to report substantial losses. Institutional investors currently hold 52.05% of the company's stock.
Absci Corp. Advanced Charts | ABSI
This page provides advanced chart data and detailed financial information for Absci Corp. (ABSI), including real-time stock quotes, analyst ratings, key financial metrics, and company profile. It also offers a comparison with peer companies in the biotechnology and pharmaceutical sectors.
Insiders See US$933.2k Investment In Absci Jump Last Week
Insiders at Absci Corporation saw a significant return on their investments, with a US$933.2k purchase now worth US$3.06m after the stock gained 21%. While insiders bought shares over the last year, notably one Co-Chair purchased US$229k worth of shares at a price significantly lower than the current market price, suggesting confidence but not necessarily at today's valuation. Absci insiders collectively own 4.6% of the company, valued at US$87m, indicating some alignment with shareholders.